共 50 条
Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma
被引:11
|作者:
Jubelin, Camille
[1
,2
,3
]
Munoz-Garcia, Javier
[2
]
Cochonneau, Denis
[2
]
Moranton, Emilie
[2
]
Heymann, Marie-Francoise
[2
]
Heymann, Dominique
[1
,2
,4
]
机构:
[1] Nantes Univ, CNRS, US2B, Biol Sci & Biotechnol Unit,UMR 6286, F-44000 Nantes, France
[2] Inst Cancerol Ouest, Tumor Heterogene & Precis Med Lab, Blvd Jacques Monod, F-44805 St Herblain, France
[3] Atlantic Bone Screen, F-44800 St Herblain, France
[4] Univ Sheffield, Med Sch, Dept Oncol & Metab, Sheffield S10 2RX, S Yorkshire, England
关键词:
Cancer stem cells;
bone sarcoma;
soft tissue sarcoma;
drug resistance;
tumor microenvironment;
recurrent disease;
residual disease;
LIPID-POLYMER NANOPARTICLES;
CD133;
EXPRESSION;
LUNG METASTASIS;
SUPPRESSES;
INCREASES;
CHEMORESISTANCE;
ACTIVATION;
INVASION;
SURVIVAL;
IDENTIFICATION;
D O I:
10.20517/cdr.2021.130
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Sarcomas are a large family of cancers originating in the mesenchyme. Composed of more than 100 histological subtypes, soft tissue and bone sarcomas remain clinically challenging, particularly in children and adolescents in whom sarcomas are the second most common malignant entities. Osteosarcoma is the main primary bone tumor in adolescents and young adults and is characterized by a high propensity to induce distant metastatic foci and become multi-drug resistant. The innate and acquired resistance of osteosarcoma can be explained by high histological heterogeneity and genetic/molecular diversity. In the last decade, the notion of cancer stem-like cells (CSCs) has emerged. This subset of cancer cells has been linked to drug resistance properties, recurrence of the disease, and therapeutic failure. Although CSCs remain controversial, many elements are in favor of them playing a role in the development of the drug resistance profile. The present review gives a brief overview of the most recent biological evidence of the presence of CSCs in osteosarcomas and their role in the drug resistance profile of these rare oncological entities. Their use as promising therapeutic targets is discussed.
引用
收藏
页码:184 / 198
页数:15
相关论文